Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective

Menezes, Fabiana Gatti de; Abreu, Rodrigo Martins; Itria, Alexander

doi:10.5935/0101-2800.20160048

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously published cost-effectiveness analyses of vitamin D receptor activators and/or calcimimetics used to treat SHPT in patients with CKD were based on the assumed relationship between modifiable laboratory parameters (e.g. iPTH and 25(OH)D) and CV outcomes [48][49][50] .…”

Section: Discussionmentioning

confidence: 99%

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

Kalantar-Zadeh

Hollenbeak

Arguello

et al. 2019

Journal of Medical Economics

View full text Add to dashboard Cite

Aims: Patients with chronic kidney disease (CKD) not on dialysis frequently have vitamin D insufficiency (VDI) and secondary hyperparathyroidism (SHPT), which are associated with an increased risk of cardiovascular (CV) disease, fracture, CKD progression, and death. This study estimated the cost-effectiveness of extended-release calcifediol (ERC) vs paricalcitol for the treatment of patients with CKD stages 3-4 that have SHPT and VDI. Materials and methods: An economic analysis of SHPT treatments among a hypothetical cohort of 1,000 patients with CKD Stage 3 and 4 with SHPT and VDI was developed to estimate differences in the rates and costs of CV events, fractures, CKD stage progression, and mortality in patients treated with ERC and paricalcitol. A Markov model was developed with 1-year cycles and a 5-year time horizon from a US Medicare payer perspective with costs valued in 2017 US dollars. Results: The outcomes of the model were rates of clinical events, total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). Across a 1,000-person cohort, ERC was the dominant (less costly, more effective) treatment strategy when compared with paricalcitol. Treatment with ERC resulted in cost savings of $14.8 M (95% CI ¼-$10.0 M-$45.2 M) and an incremental gain of 340 QALYs (95% CI ¼ 200-496) compared to treatment with paricalcitol. Limitations: Bridging biochemical levels to clinical outcomes may not represent real-world risk of the clinical events modeled. Future real-world outcomes of patients treated with ERC and paricalcitol may be used to evaluate the model results. Conclusions: This model demonstrated favorable short-and long-term clinical benefits associated with the use of ERC in patients with CKD Stage 3 and 4 with SHPT and VDI, suggesting ERC may be cost-effective from the Medicare perspective compared to paricalcitol.

show abstract

Section: Discussionmentioning

confidence: 99%

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

Kalantar-Zadeh

Hollenbeak

Arguello

et al. 2019

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…То есть лечение пари-кальцитолом можно считать экономически оправданным согласно рекомендациям ВОЗ от 2013 г. [32].…”

Section: рисунок химическая структура парикальцитолаunclassified

Diagnosis and Treatment of Patients With Secondary Hyperparathyroidism and Renal Insufficiency. Therapeutic Potential of Paricalcitol

Белая¹,

Рожинская²

2017

Med. sov.

View full text Add to dashboard Cite

show abstract

“…Therefore, here we choose calcitriol and cinacalcet as references to explore the cost-effectiveness analysis of Paricalcitol. The cost-effectiveness of paricalcitol has been proved in Italian, US, UK, Brazil, German (13,(31)(32)(33)(34). We aim to explore the cost-effectiveness of paricalcitol in China.…”

Section: Introductionmentioning

confidence: 99%

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis

Zhang

Cai

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Background: Chronic Kidney Disease (CKD) is a global chronic disease with increasing prevalence in recent years, particularly CKD accompanied by Secondary Hyperparathyroidism (SHPT) leads to reduced quality of life, increased mortality, a considerable economic burden for patients and society. The aim of this study was to investigate the cost-effectiveness analysis of paricalcitol vs. calcitriol + cinacalcet for CKD patients with SHPT in China in 2020.Methods: A Markov model was conducted employing data derived from published literature, clinical trials, official sources, and tertiary public hospital data in China, based on a 10-year horizon from the perspective of the healthcare system. Calcitriol + Cinacalcet was used as the reference group. CKD stage 5 (CKD-5) dialysis patients suffering from SHPT were included in the study. Effectiveness was measured in quality-adjusted life years (QALYs). The discount rate (5%) was applied to costs and effectiveness. Sensitivity analysis was performed to confirm the robustness of the findings.Results: The base case analysis demonstrated that Patients treated with paricalcitol could gain an increase in utility (0.183 QALYs) and require fewer expenditures (6925.612 yuan). One-way sensitivity analysis was performed to showed that impact factors were the price of cinacalcet, the hospitalization costs of patients with paricalcitol and calcitriol, the costs and utilities of hemodialysis and the costs of calcitriol, the costs of paricalcitol regardless of period. Probabilistic simulation analysis displayed when willingness-to-pay was ¥217113, the probability that Paricalcitol was dominant is 96.20%.Conclusion: The results showed that paricalcitol administrated to treat patients diagnosed with Secondary hyperparathyroidism in Chronic Kidney Disease, compared to calcitriol and cinacalcet, might be dominant in China.

show abstract

Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective

Abstract: According to cost-effectiveness threshold recommended by the World Health Organization for 2013, the treatment of SHPT in patients on dialysis with paricalcitol is cost-effective when compared to calcitriol, from the public healthcare system perspective, in Brazil.

Cited by 7 publications

References 0 publications

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3–4 CKD

Diagnosis and Treatment of Patients With Secondary Hyperparathyroidism and Renal Insufficiency. Therapeutic Potential of Paricalcitol

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis

Contact Info

Product

Resources

About